Akorn (AKRX) : Mondays money flow data in Akorn (AKRX) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $12.95 million, whereas, $4.72 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 2.74, in favor of the bulls. The total money flow into the stock was $8.22 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $8.75 million. The total value of block trades done on upticks was $8.75 million. Akorn (AKRX) fell $0.02 and traded at $31.16, down -0.06% for the day, over previous days close. On a weekly basis, the shares are 1.63% over the previous weeks close.
Akorn, Inc. is up 17.45% in the last 3-month period. Year-to-Date the stock performance stands at -15.95%. Shares of Akorn, Inc. rose by 1.46% in the last five trading days and 6.67% for the last 4 weeks. In a related news, The officer (Sr VP Gen Counsel & Secretary), of Akorn Inc, Bonaccorsi Joseph had unloaded 6,500 shares at $29.84 per share in a transaction on June 14, 2016. The total value of transaction was $193,960. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Akorn (NASDAQ:AKRX): stock turned positive on Monday. Though the stock opened at $31.42, the bulls momentum made the stock top out at $31.89 level for the day. The stock recorded a low of $31.07 and closed the trading day at $31.36, in the green by 0.58%. The total traded volume for the day was 1,632,694. The stock had closed at $31.18 in the previous days trading.
Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.